Verastem Inc. (2VS.SG)
| Previous close | 0.3799 |
| Open | 0.3752 |
| Bid | 0.3760 x 500000 |
| Ask | 0.4166 x 500000 |
| Day's range | 0.3752 - 0.3752 |
| 52-week range | 0.2798 - 1.6130 |
| Volume | |
| Avg. volume | 306 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 08 May 2023 - 12 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
BOSTON, March 15, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of Let’s Talk About LGSOC, a new initiative that calls attention to low-grade serous ovarian cancer (LGSOC). Let’s Talk About LGSOC provides detailed information about LGSOC and its symptoms, its differences from the more common high-grade serous ovarian cancer (HGSOC), tips and resources, and ways to connect with others
- Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
BOSTON, March 14, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted recent progress.
- Business Wire
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
BOSTON, February 02, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcoming catalysts to support its lead compound RAF/MEK clamp avutometinib in RAS pathway-driven cancers.
